uveitis

Regeneron booth at AACR 2026
Biotech

Regeneron ends eye disease trial following safety review

The Titan study tested REGN7041, an anti-CD3 monoclonal antibody, in patients with inflammation of the uvea, the eye’s middle layer.
Darren Incorvaia Aug 17, 2026 2:30pm
Wall Street IPO initial public offering markets shares stock

Alumis downsizes IPO, tacks on private placement

Jun 28, 2024 5:02am
Photo of Wall Street street sign with american flags in the background

Alumis eyes $300M IPO to fund clinical-stage TYK2 pipeline

Jun 24, 2024 8:14am
Graphic image of the letters IPO in white in front of a yellow background

Alumis plans IPO to fund TYK2 inhibitor through phase 3 trials

Jun 10, 2024 8:35am
long shot miss basketball hoop fail shoot

Roivant ends longshot lupus program after phase 2 fail

Nov 27, 2023 9:48am
Nasdaq

Acelyrin eyes IPO boost to $400M haul to take on Lilly, Novartis

Apr 14, 2023 6:10am